PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Inclusion Criteria: * Age ≥ 18 ≤ 75 years；no gender limitations * Histopathologically and/or cytologically confirmed ductal adenocarcinoma of the pancreas, the patient has fresh pathological tissue and the tumour is located in the head and neck or body of the pancreas * Locally advanced pancreatic cancer, borderline resectable or unresectable, without metastases. * Life expectancy \>= 3 months. * ECOG score 0-1. * Have at least 1 measurable lesion according to RECIST 1.1 criteria. * No prior treatment with abdominal radiotherapy, chemotherapy and PD-1/PD-L1 antibody. * Adequate organs functions as defined by the following laboratory values (completed within 14 days prior to registration): (1) haemoglobin \>= 90 g/L (no blood transfusion within 14 days)； (2) neutrophil count \> 1.5x10\^9/L； (3) platelet count \>= 100x10\^9/L； (4) total bilirubin \<= 1.5xULN (upper limit of normal)； (5) blood glutamic transferase (ALT) or blood glutamic transferase (AST) \<= 2.5xULN (6) endogenous creatinine clearance \>= 60 ml/min (Cockcroft's AST). (ALT) or blood albumin transaminase (AST) \<= 2.5xULN； (6) endogenous creatinine clearance \>= 60 ml/min (Cockcroft-Gault formula)； (7) cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) \>= 50%. (8) International normalised ratio (INR) of prothrombin time ≤ 1.5 and partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal in patients who have not received anticoagulation. Patients receiving full or par…